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Objectives: A factor contributing to the value of patient preference studies is patient
centricity. This study aimed to explore how patients want to be involved in the design and
conduct of patient preference studies. In addition, we investigated patients’ expectations
regarding the communication of study results back to patients.
Methods: Semi-structured interviews were conducted with patient representatives
within three different disease areas: rheumatic diseases, cancer, and neuromuscular
disorders. For each disease area, interviews were conducted with interviewees from
Belgium, the Netherlands and the United Kingdom. Interviews followed a predefined
interview guide covering topics relating to timing, level, and requirements for patient
involvement in patient preference studies, as well as communication of results. Interviews
were audio-recorded, transcribed and analyzed using framework analysis in NVivo 12.
Results: A total of 14 interviews were conducted. Some interviewees believed
that patients should be involved in all steps of a patient preference study. Patient
involvement seemed most valuable during the design phase to support defining
research questions and instrument design. During analysis, patients can be involved for
optimal interpretation of results. Most interviewees mentioned that patient involvement
should be on the level of advice or collaboration, not control. Interviewees expressed
requirements for patient involvement relating to the knowledge of the involved patient,
time investment, compensation and other incentives. Regarding communication of
results, most interviewees wished to receive a brief and lay summary of the results,
followed by a detailed explanation of both individual and average results accompanied
by visuals.
Conclusions: Patient involvement in patient preference studies could increase question
comprehension by study participants and ensure correct interpretation of results by
researchers. Patients want to be involved as advisors or collaborators, and considering
their personal situation as well as establishing agreements on roles, time involvement and
compensation early on will result in a most optimal partnership.
Keywords: patient involvement, patient participation, patient engagement, patient preferences, patient
perspectives
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HIGHLIGHTS
- Patients can be involved in defining research questions, as well
as questions, attributes and levels for patient preference studies
- Patient involvement could lead to more optimal interpretation
of patient preference study results
- Patients appreciate to be involved as advisors or collaborators
- Enough educational and compensational support should be
provided to allow a fair involvement
- Patients wish to be involved through multiple short sessions
INTRODUCTION
The health care system is undergoing a paradigmatic shift and
the role of patients is evolving from being passive recipients
to becoming autonomous and actively involved participants
(1). Patients are increasingly involved in healthcare decision-
making at the micro level, also referred to as individual patient
involvement or shared-decision making (2, 3). Experiential
knowledge, the kind of expertise that is gained by patients
through experiencing illnesses and therapies, is increasingly
considered complementary to health care professionals’ expertise
(4, 5). Beyond decisions related to their personal healthcare,
patients are also increasingly requested to take on active roles
in drug development, e.g., provide input in clinical trial design,
scientific advice procedures, discussions with regulators and
health care policy decision-making at the meso and macro level;
also referred to as collective patient involvement (3–7). Abma and
Broerse (8) defined different levels of patient involvement from
consulting as study subject to obtaining control as client.
While collective patient involvement increasingly occurs,
this direct form of patient involvement is criticized by some
as doubt exists on whether one patient or a small number
of patients can represent the views of the majority (9, 10).
Patient preference studies explore, measure and assess treatment
preferences of patients and are a tool to incorporate the voice
of a larger group of patients in the medical product life cycle
(e.g., in value assessments like benefit-risk assessment and health
technology assessment). Use of patient preferences in itself can
be seen as a form of indirect patient involvement (10). The
Patient Preferences in Benefit-Risk Assessments during the Drug
Life Cycle (PREFER) project aims “to strengthen patient-centric
decision-making throughout the life cycle of medicinal treatments
by developing expert and evidence-based recommendations on
how patient preferences should be assessed and inform decision-
making” (11). A factor contributing to the value of patient
preference studies is patient centricity, referring to the extent to
which patients are involved in the design and conduct of these
studies (12–14). The Food and Drug Administration (FDA) also
recognized this and stated in their guidance on patient preference
information (15) that the patient should be “the central focus of
the study.”
The European Patients’ Academy (EUPATI) created, together
with patients, guidance on patient involvement in development,
ethical review of clinical trials, regulatory evaluation and health
technology assessment of drugs (6, 7, 16–18). While guidance
exists on patient involvement in these processes, it remains
unknown how to involve patients in patient preference studies.
The aim of this study was to explore how and when patients want
to be involved along the design and conduct of patient preference
studies, as well as to understand the expectations of patients
regarding communication of study results back to participants.
METHODS
Population
Semi-structured interviews were conducted with patient
representatives within three different disease areas: rheumatic
diseases (RD), cancer (CA), and neuromuscular disorders
(NMD). Patient representatives had been involved in activities
of patient organizations or patient preference research, and were
either patients themselves or caregivers to a patient. Caregivers
were defined as parent(s), legal guardian, or other adult family
member living in the same house or in contact with the patient
in a caregiver relationship at least 4 times/weeks for at least 1 h
or more, and were only included in the sample if the patient
could not participate in the interview due to age (pediatric
patients) or cognitive impairments. The three disease areas
selected (i.e., RD, CA, and NMD) represent diseases that vary
not only by disease phenotype but also in prevalence, chronicity,
and medical unmet needs. For each disease area, interviews were
conducted with interviewees from Belgium, the Netherlands, and
the United Kingdom (UK). These three countries were selected
as they cover different patient involvement cultures. While
the Netherlands has a highly developed patient involvement
model (19), the UK has less formalized processes but is still
reaching high patient involvement (20), and Belgium has low
and scattered patient involvement (10).
Interview Guide
An interview guide was established (Supplemental Material I)
based on the findings of previous PREFER studies that
highlighted the need for patient involvement in the different
phases of patient preference studies (12, 13), and on levels of
patient involvement as discussed by Abma and Broerse (8). The
interview guide consisted of parts relating to (1) interviewees’
experience and knowledge on patient involvement and patient
preference studies, (2) patient involvement in design and conduct
of patient preference studies, and (3) communication of results to
patients. The guide was written in lay language and was piloted
in an interview with a representative of EUPATI Belgium. To
prevent the interview guide from becoming disease-specific, no
patients from the target populations were involved in the design.
The interview guide was subsequently translated from English to
Dutch for interviews in Belgium and the Netherlands, allowing
interviewees to express themselves in their native language.
Participant Recruitment
Interviewees were recruited via mail through purposive sampling
and snowballing using the network of EUPATI Belgium and
PREFER. In purposive sampling, interviewees are chosen based
on their ability to provide insights regarding the study purpose
(21). In this study, patient representatives were chosen as
subjects because of their expertise in their disease and patient
Frontiers in Medicine | www.frontiersin.org 2 March 2020 | Volume 7 | Article 93
van Overbeeke et al. Patient Centricity in Patient Preference Studies
involvement or patient preferences. The goal was to interview
at least one, preferably two, patient representatives per disease
category per country.
Conduct
Semi-structured interviews were executed in person or through
teleconference. During the interviews, the interview guide was
used to present an example of a patient preference study
specific to the disease area of the patient representative, and
to ask predetermined questions. However, open discussion was
also encouraged to explore opinions in-depth. After informed
consent was given, a short demographics and health literacy (22)
questionnaire was completed. Interviews were audio-recorded
and then transcribed verbatim. All the transcripts of the
interviews were produced in the original language and non-
English quotes were only translated to English upon inclusion in
the paper.
Analysis
The transcripts were analyzed using NVivo 12 following
framework analysis, a type of thematic analysis (23)
(Supplemental Material II). The analysis started with a
familiarization process, including conducting, transcribing
and reading interviews, to ensure that researchers obtained an
overview of the dataset. Themes of the interview guide informed
the creation of deductive codes. The first 4 transcripts were
independently coded by two researchers (IV and EvO) and then
compared. Based on observed patterns and critical observations
inductive codes were created. The inductive and deductive
codes together formed a “coding tree.” The coding tree was
uploaded in NVivo and applied to all transcripts, where sections
of transcripts relating to a particular theme were classified under
the respective code. All data were summarized into a framework
matrix. The data of the interviews were interpreted, summarized
per code, and some quotes of individual interviewees were added
for clarification.
RESULTS
In total 14 interviews were conducted (Table 1). More female
than male patient representatives and no adolescents were
recruited. Almost all interviewees were patients themselves; only
oneNMD caregiver was recruited in the Netherlands. The sample
included one or more patient representatives per disease area
per country and most interviewees had adequate health literacy
(i.e., a health literacy score of <2). Results of the interviews
are described below per theme. Codes following quotations refer
to interviewees’ characteristics: BE, Belgium; CA, cancer; NL,
the Netherlands; NMD, neuromuscular disorders; RD, rheumatic
diseases; UK, United Kingdom.
The Meaning of the Term “Patient
Preferences” to Patients
Patients were asked to explain their understanding of the term
“patient preferences.” Interviewees described patient preferences
as what patients find important in their experience of the illness,
how they experience their quality of life and what is needed to
TABLE 1 | Demographics.
Characteristics Interviewees (n = 14)
n %
Sex
Females 9 64,29
Males 5 35,71
Age, Years
18–24 0 0
25–39 3 21,43
40–60 9 64,29
>60 2 14,29
Country
United Kingdom 4 28,57
Netherlands 3 21,43
Belgium 7 50
Disease Area
Neuromuscular disorders 5 35,71
Rheumatic diseases 5 35,71
Cancer 4 28,57
Stakeholder Group
Patient 13 92,86
Caregiver 1 7,14
Years Since Diagnosis
<1 0 0
1–3 1 7,14
4–10 6 42,86
>10 6 42,86
Health Literacy
Adequate 11 78,57
Inadequate 3 21,43
improve that quality. They expressed that patient preferences are
very individual. In addition, they stated that patient preferences
represent the right to have the choice to accept or refuse
treatments. “Preferences should be taken into account during all
parts of the journey: from diagnosis right through the stages of
treatment and side effects” (CA_UK_13). It was stated that patient
preferences are also about developing drugs in a way that patients
want them to be developed. AUK cancer interviewee emphasized
that not only patients’ preferences, but also the partner and
family’s preferences should be considered.
When the definition of patient preferences and the example of
a patient preference study were presented to the interviewees, all
14 interviewees understood that patient preferences cover health
treatment choices, and that a comparison and preference is made
based on received information covering the different options.
One suggested the term “treatment preferences” as a possible
synonym for patient preferences (CA_NL_14).
Patient Involvement Along the Phases of
Patient Preference Studies
Interviewees were asked in which steps of a patient preference
study they thought their input as a patient could be of
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most value and why. Opportunities and challenges for
patient involvement along the different phases of patient
preference studies were identified (Figure 1). According
to five interviewees, patients should be involved in all
steps of a patient preference study. Involvement of
patients was especially found valuable in the set-up of
the study. Involving patients early-on would also allow
patients to be aware of every aspect and decision made in
the study.
Defining Research Questions
Having patients involved in defining research questions was
found important by five interviewees. Involving people from
the start, gives patients and researchers the opportunity to
discuss the need and initial considerations for the study.
Patients can be involved in defining research questions by
either proposing them, or by providing suggestions to refine
those proposed by researchers. Three interviewees from Belgium
thought that it would be difficult for patients to define
research questions for patient preference studies, since (1)
experience with this kind of studies is required and a lot of
patients are not aware of the existence of patient preference
studies, and (2) patients should be aware of needs of the
full patient population to propose relevant research questions.
Interviewees agreed that there is value in involving patients in
the prioritization and refinement of research questions based
on their unmet needs; “Having life experience always helps to
filter out ideas” (NMD_UK_6). A benefit of involving patients
in defining research questions, as suggested by interviewees, was
that it could prevent misunderstandings in further phases of
the study.
Sample Definition
While half of the interviewees mentioned that patients could
be involved in defining the patient sample, they considered
professionals to be better placed than patients to make
these decisions. Two Belgian interviewees explicitly stated that
the patient sample should not be defined by patients. One
interviewee explained that it is difficult for patients to define
inclusion and exclusion criteria. On the other hand, another
interviewee felt that defining the target patient population should
be “quite clear” (RD_BE_1).
Preference Method Selection
Two interviewees mentioned that patients could be involved in
the selection of preference exploration or elicitation methods.
They believed it was valuable to discuss with patients how
preferences should be measured to address concerns regarding
features of these methods, like the duration of a survey.
Instrument Design
Ten interviewees elaborated further on involving patients in the
design of questions, attributes, and levels. They believed patients
could help design or formulate the questions. Interviewees
recognized that formulation is important and has to be
checked with patients as small nuances could result in study
participants having “different degrees of how they understand
things and interpret things” (NMD_UK_2). A cancer patient
from the Netherlands stated that patients are increasingly
being involved in the design of questions for interviews and
surveys. Interviewees also mentioned that based on the patients’
experience with treatments that they can suggest inclusion of
attributes relating to treatment (side) effects that professionals
may have not considered important. Involving patients in the
FIGURE 1 | Overview of opportunities and challenges for patient involvement in patient preference studies (PPS). Opportunities (green) and challenges (red) were
identified in interviews with patient representatives.
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design of instruments could, according to interviewees, lead
to the creation of surveys of reasonable length; to prevent
researchers from asking too much at once, e.g., “we will measure
this too, and this seems also interesting” (RD_BE_3), and to
prevent patients from getting tired, losing their concentration,
and providing inaccurate answers.
Participant Recruitment
Seven interviewees felt that patient organizations, not individual
patients, could play an essential role in recruiting participants
for patient preference studies, as they often have direct
access to patient databases. Patient organizations could provide
“access and information” (CA_NL_14) to the study on their
website or via brochures. Furthermore, patients could also
try to directly convince and “motivate” (RD_NL_8) others
in their environment to participate in patient preference
studies. Interviewees expressed that patients are more likely
to be convinced to participate in studies “by fellow patients”
(RD_BE_3) or “experience experts” (RD_BE_5) than “by a
researcher who sends yet another email or letter” (RD_BE_3).
Data Collection
Seven interviewees shared the opinion that collecting data is not
particularly a step where patients could be involved. Collecting
preferences was seen as a task for researchers as it requires an
“analytical mindset” (RD_BE_5). Nevertheless, five interviewees
indicated that there was a role for patients during data collection.
Two interviewees stated that participants in a patient preference
study might not understand the questions asked to them and that
a patient could accompany the researcher to comfort participants
and explain the questions; “patients might understand better if it’s
explained to them by somebody who knows what it’s like to live with
that disease” (RD_UK_12). This was found particularly useful for
specific populations like “elderly” or “people with lower health
literacy” (CA_NL_14). It was suggested by two interviewees
that patients could also be involved through pilot interviews to
test questions.
Analysis and Interpretation of Results
Interviewees believed that the analysis of patient preference
studies should be done by trained professionals. Nine
interviewees shared the opinion that it would be valuable
to involve patients in interpretation of results, to identify
nuances. An NMD interviewee from Belgium stated that it could
be difficult for researchers to interpret an answer without having
experience with the disease context. A Belgian RD interviewee
commented that interpretation can take place on multiple levels;
ranging from looking at “raw data” trying to gain insights, to
looking at processed results in order to clarify the interpretation.
Two interviewees from Belgium did not find it necessary to
involve patients in analysis and interpretation.
Levels of Patient Involvement in Patient
Preference Studies
The interviewees were asked what roles patients want to have
in patient preference studies along different involvement levels
(Figure 2). The four levels that were presented to interviewees
were consultation, advice, collaboration, and control. An
interviewee from the Netherlands mentioned a fifth level of
patient involvement, based on own experience, where patients
can act as observers in meetings to ensure voices are well-
balanced. Six interviewees stated that patients can be involved
FIGURE 2 | Staircase of patient involvement levels in patient preference studies (PPS). Roles of patients and patient involvement levels were identified through
interviews and the patient participation model of Abma and Broerse (8), and are displayed from passive to active involvement.
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in all levels. The level of involvement that a patient can take on
seemed to depend on patient-related factors like “stage of disease”
(RD_BE_3), but also study-related factors as described below.
Consultation
Half of the interviewees mentioned that a lot of patients would
want to participate in patient preference studies as subjects.
Interviewees argued that some patients might think they do not
have enough knowledge and would be scared to take on a more
involved role. A Dutch interviewee strongly felt that consultation
as study subjects cannot be considered to be patient involvement
and stated it is “a necessity and not part of including patient’s
perspectives” (NMD_NL_10).
Advice
Most of the interviewees felt that giving advice on the design and
conduct of patient preference studies, was an adequate level of
patient involvement. Interviewees mentioned that advising roles
require “a little preparation” and that patients taking up these
roles should be “people who have more than just basic knowledge”
(RD_BE_1). Patients might advise researchers on “what patients
know” (NMD_UK_2) and what their needs are. However, one
interviewee argued that it is very difficult to find people capable of
giving “good advice” (NMD_BE_9) as patients may have limited
medical knowledge or may be desperate for treatments.
Collaboration
Almost every interviewee argued that patient involvement
on a collaborative level, as research partners, would be very
valuable. Working with researchers in a collaborative approach
might involve patients actively “brainstorm(ing) about the design
and what should be investigated” (RD_BE_1), giving input in
decisions that need to be made to obtain “relevant research”
(NMD_NL_10), having the opportunity “to really follow things
up” in order to “share it afterwards” (RD_BE_5), and “work(ing)
with the participants” (RD_UK_12) by helping other patients to
complete a survey or interview. It was suggested to find people
suited for this role via patient organizations. Two interviewees
stressed that patients need to have the time and energy to
collaborate; “patients are volunteers and some patients are not well
enough to commit fulltime” (CA_UK_13). A Belgian interviewee
emphasized the importance of giving collaborating patients
“sufficient support” (RD_BE_5).
Control
It was advised by the majority of interviewees not to put patients
in control of patient preference studies, but to leave this to
trained researchers. They felt that it cannot be expected from
patients to be aware of all ongoing scientific research and that
reversing the roles would be less effective. Three interviewees
mentioned that patient organizations possess the know-how and
could potentially be in control of patient preference studies.
Requirements for Patient Involvement in
Patient Preference Studies
Interviewees were asked about requirements for patient
involvement relating to skills, time investment, incentives and
barriers. Open communication and pre-defined arrangements
regarding expectations, commitment, compensation and
personal situation will, according to the interviewees, result in
comfortable, and pleasant collaboration.
Skills
Interviewees mentioned skills that are required of patients
involved as advisors or collaborators. These requirements
included (1) “sufficient mental capacities” (NMD_BE_11), (2)
disease knowledge, (3) experience with research, (4) familiarity
with “the jargon” (CA_NL_14), (5) drive and motivation, (6)
skills in the “political, strategic game” (NMD_NL_10), and (7)
capable of “transcending their own disease situation” (RD_BE_3)
to be aware of the perspective of the whole patient population.
A UK interviewee felt that patients who are part of patient
organizations, are automatically a “certain type of persons”
(RD_UK_12) and can easily be involved in design or conduct
of patient preference studies. Three interviewees shared the
opinion that “a variety would be good” (NMD_UK_2); having a
combination of patients with and without experience.
Time Investment
In general, interviewees stated that there are definitely patients
willing to invest time in patient preference studies. The time
and energy that patients would be willing to invest depends,
according to the interviewees, on different factors. Patient-
related factors seemed to include (1) work situation, (2) family
circumstances, (3) treatment plan, and (4) personal interests
and expectations. Study-related factors included (1) provision of
financial compensation, (2) flexibility, and (3) the desired level
of patient involvement. Interviewees estimated a reasonable time
investment for patients to be “one to 2 h a week” (RD_BE_1) to
half a day per week, and stated that the number of consecutive
hours that patients are requested to be involved should be
limited to 3 h. In general, interviewees preferred multiple short
durations of involvement over long consecutive periods. Two
interviewees were willing to “give as much time as needed to this
cause” (NMD_UK_6). All interviewees expressed the importance
of having expectations agreed upon beforehand and that time
should be used efficiently.
Incentives and Barriers
Almost every interviewee showed willingness to be involved
in design and conduct of patient preference studies. Four
interviewees did not need any incentives, and argued that
the value of patient preference studies for future drug
development would be sufficient. Barriers that could impede
patient involvement were: (1) too much time and energy asked
from patients, (2) difficult accessibility of research meetings,
(3) the use of technical medical terms, and (4) patients’
physical condition and treatment plan. Incentives of interest to
patients included: (1) patient-relevant study objectives, (2) good
collaboration between all stakeholders, (3) extensive briefing on
the purpose of the study, and expectations and timing of the
involvement, and (4) providing the possibility to complete tasks
from their own homes “in the time that suits them” (RD_UK_12)
and attend meetings online, (5) financial compensation, and (6)
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sufficient support from the research team. Regarding financial
compensation, seven interviewees stated that the expenses (e.g.,
travel expenses) resulting from their involvement should be
covered. Financial incentives that go beyond reimbursement of
travel expenses, would be “a definite enticement” (RD_UK_12)
and were mentioned as a requirement by three interviewees.
Two interviewees argued that patients should be financially
compensated in proportion to the time and energy invested.
A Dutch cancer interviewee insisted that compensating the
time invested by patients shows that their involvement is taken
seriously by the research team. Other incentives like vouchers,
provision of alimentation, co-authorship on a publication,
and arranged transport were suggested as alternatives for
financial compensation.
Communication of Patient Preference
Study Results to Patients
The final theme discussed with all interviewees was on how
to communicate patient preference study results to patients.
First, the value of communicating study results to patients
was discussed, followed by how results should be presented
to patients. Patients wanted to receive results for their own
education and interest. The majority of interviewees would want
to receive a brief lay summary of the results, followed by a
detailed explanation to have the opportunity to explore the results
in depth. Interviewees stated that results should be “reduced
to the essence” (NMD_BE_9), without leaving out important
results. Eleven interviewees preferred text to be accompanied by
graphs or other visuals. In addition, almost every interviewee
wanted to receive both individual and average results, in a way
that they would be able to compare their individual results
with the group average. One interviewee questioned “whether
it would help” (NMD_UK_2) to receive information on other
patients’ preferences, given that in some disease areas severity
and symptoms of disease can vary largely between patients. A
Belgian RD interviewee felt that it could be dangerous to compare
individual results to the average, as it can be perceived as if
participant’s preferences are judged.
DISCUSSION
This qualitative study builds on results from previous research
describing the value of patient centricity in patient preference
studies and need for more research on how patients can be
involved (12, 13). Therefore, the purpose of this study was
to investigate how and when patients want to be involved in
the design and conduct of patient preference studies. Roles,
levels and requirements for patient involvement, as well as
communication of results to patients, were discussed with
patient representatives.
Roles and Levels of Patient Involvement in
Patient Preference Studies
According to interviewees, patient involvement in patient
preference studies is most valuable when defining research
questions, defining instruments (questions, attributes, levels)
and interpreting results. Emphasis was placed on involving
patients from the beginning to discuss unmet needs and refine
research questions. A similar mindset can be observed in drug
development and clinical trial design. Geissler et al. (24) discuss
the vital role of patients at early stages of drug development,
where priorities can be aligned with patients’ unmet needs.
Similarly, Crocker et al. (25) showed how early patient
involvement in clinical trial design can prevent researchers
from conducting trials that are not of value to patients.
Involving patients in formulating questions, attributes and
levels, for patient preference studies can ensure understanding
by study participants. The FDA guidance on PPI explains
that comprehension by study participants is important and
a full understanding of harms, risks, benefits, and other
communicated medical information is vital to obtain valid
patient preference study results (15). Differently than what
has been described about patient involvement in clinical trial
design, interviewees pointed out the importance of including
patients during the interpretation of patient preference study
results (6, 24). This difference can be explained by the nature
of data resulting from clinical trials and patient preference
study. While results of clinical trials are clinical data and not
much open for interpretation, results from patient preference
studies are mostly based on subjective perceptions of treatment
features. Involving patients when interpreting patient preference
study results can provide insights into the reasons why patients
answer in a certain way or give importance to certain features
over others.
The majority of interviewees believed that patients should
be involved in patient preference studies as advisors or
collaborators, but not as the ones being in control. This
result confirms the statement of Abma and Broerse that
partnership between involved patients and researchers has
been preferred over delegated power and citizen control (26).
Moreover, our results show the importance of early agreement
on the expected level of involvement and its implications.
The EUPATI guidance document for R&D also states that the
level of input should be discussed and agreed at start (6).
In addition, our results show that not all patients can be
involved at all levels and that agreements should reflect patients’
personal requirements.
While interviewees in general seemed to agree on the roles
and levels of patient involvement, some differences in attitudes
toward patient involvement were identified. Some of these
differences seemed to be associated with the interviewee’s county
of origin. Interviewees from the Netherlands believed in active
patient involvement and had a clear view on what they perceived
to be patient involvement (e.g., one patient representative
proposed a fifth level of patient involvement, and another
did not consider “consultation” to be patient involvement),
while interviewees from Belgium were less confident. Belgian
interviewees perceived barriers like limited knowledge and
capacities of patients, and some did not think patients were
able to define research questions and patient samples or provide
valuable input in interpretation of results. These results show
that patient involvement in patient preference studies can also
be hampered by cultural beliefs.
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Requirements for Patient Involvement in
Patient Preference Studies
Most of the interviewees believed that patients should be aware
of the perspectives of a whole patient population, transcending
their own disease, in order to take on highly involved roles
in the design and conduct of patient preference studies. The
interviewees tended to prefer patient advocates and patient
experts of patient organizations over “lay patients” as candidates
for involvement in patient preference studies. These results are
not in line with the EUPATI guidance for patient involvement in
industry led drug R&D that states that all types of patients should
be involved (6). This difference may originate from a lack of
confidence in “lay” patients regarding their knowledge on patient
preference studies that could be improved with appropriate
training and support from researchers. Harrison et al. (27)
indicate that giving training to patients and researchers on the
content of the study and on patient-researcher collaboration is
an important “best practice activity”. From the heterogeneity of
responses gathered in this study on roles and levels of patient
involvement, it can also be concluded that it would be preferable
to involve multiple patients (more than one individual) in patient
preference studies as opinions on study design and conduct may
also differ among patients.
Regarding the time that patients are willing to invest to be
involved in patient preference studies, our results showed that
this time differs between individuals and depends on various
personal and study-related factors but that full-time or long
consecutive hours would not be feasible. Interviewees with RD
were most concerned about time constraints when combining
work schedule and personal life. Cancer and NMD interviewees
highlighted the impact of their treatments on physical well-being
and the amount of energy left to dedicate to a study. If patients
are not willing or able to be involved throughout the full process,
the researchers propose to allow for flexible involvement whereby
different patients individually take on different tasks.
On the topic of incentives, more than half of our interviewees
wanted travel expenses to be covered. This confirms the
statement of Harrison et al. (27) that reimbursement of travel
expenses is an absolute minimum requirement for patient
involvement in research. Only a few interviewees expressed the
need for additional financial compensation depending on the
time and energy invested by a patient. The EUPATI guidance
for patient involvement in industry led drug R&D (6) also
recommends to provide compensation for patients’ total time
investment in addition to expenses. Harrison et al. (27) agrees
that compensating patients for their expertise and time besides
covering travel expenses is good practice. Unfortunately, there is
not always a budget for patient involvement, making financial
compensation a remaining obstacle of patient involvement
in research in general. Our results also confirmed patients’
willingness to receive non-financial compensation as proposed in
EUPATI’s guidance (6).
Communication of Patient Preference
Study Results
In the current study interviewees were asked how results
of patient preference studies should be communicated to
patients. The interviewees placed emphasis on the use
of lay language and visuals. Most interviewees wished to
receive a brief and lay summary of the results, followed
by a detailed explanation of both individual and average
results accompanied by visuals. Wolka et al. (28) went
beyond these general requirements and stated that the
communication of these results should be tailored to the
targeted patient population. While efforts should be made
to communicate results of preference studies back to
study participants, there may be barriers preventing this.
These barriers may include (1) anonymous participation of
patients in these studies, (2) the time that it takes to prepare
results for dissemination, which may exceed study funds,
investigators’ availability or participants’ expectations, and
(3) legal barriers preventing industry sponsors from having
direct contact with patients (10). In this case, we propose
to provide a summary of sample-level results to recruiting
parties (e.g., patient organizations and physicians) for them
to share with their patients and support dissemination.
Still, better strategies on how and when to communicate
results back to study participants and other patients
are needed.
Strengths and Limitations
Although interviews by nature provide subjective evidence that
may not be generalizable to other populations, our study design
safeguarded the inclusion of diverse types of patients from
three different disease areas across three countries, reducing
population specificity.
A limitation of this study is the small patient sample
included (i.e., 14 interviewees). Therefore, we should be
cautious when extrapolating conclusions. During recruitment,
we experienced low response rates that seemed to be related
to the exhaustion of patient populations. Our overall pool
of candidates was already limited to start with as we focused
on experienced patient representatives. Active and more
experienced patient representatives working for patient
organizations are increasingly being contacted by researchers,
resulting in difficulties to commit to new requests. In our study,
out of the three disease areas, cancer patient representatives
were the hardest to recruit. Another limitation is the lack
of collaborative involvement of patients throughout design
and conduct of the current study, caused by the small
pool of candidates and lack of non-disease specific patient
representatives. The researchers felt that involving patients
from one or two of the investigated disease areas could have
led to a disease-specific design, and would also have led to
an even smaller sample of candidate participants. Therefore,
the design was only discussed with a patient representative
involved in EUPATI Belgium; a non-disease specific initiative
promoting patient involvement through patient education. Due
to high demand, the EUPATI BE patient representative was not
available for further involvement in conduct and analysis stages
of the study.
Analysis of health literacy questions showed that three
interviewees had inadequate health literacy. However, the
interviewers did not experience any difficulties when discussing
patient preference studies with these interviewees. Therefore,
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the researchers believe that these health literacy scores did
not affect the results of the interviews. Moreover, these
results show that patients with inadequate health literacy are
able to understand patient preference studies and therefore
could potentially be involved in the design and conduct of
these studies.
All interviews were conducted by the same interviewer (IV),
reducing the variability between interviews. The interviewer
was a junior researcher, but was supervised and trained by
a researcher (EvO) with experience in conducting qualitative
research, including the conduct of interviews and focus
groups with patients. The analysis of the data was also done
by these two researchers as they were most familiar with
the dataset.
Future Perspectives
This qualitative study provides insights on how to, according
to patients, involve patients in the design and conduct of
patient preference studies. Further qualitative studies could
be set up to explore perspectives of other stakeholders,
such as specialized health care professionals and researchers
conducting patient preference studies, to understand how
they want to involve patients and to provide additional
insights on topics for which heterogeneity in responses was
observed among patients (e.g., the involvement of patients
in sample definition and data collection). Furthermore,
quantification of our results in a larger patient sample
could improve the generalizability of these results to a
wider population and investigate heterogeneity in responses.
Moreover, opinions from various stakeholders could be
combined in recommendations on patient involvement
in patient preference studies. As mentioned above, also
strategies on how and when to communicate results
back to study participants and other patients should be
further explored.
CONCLUSIONS
Patient involvement in patient preference studies is, according
to patient representatives, most valuable in early and late
stages of these studies; more specifically in defining research
questions, formulating questions, attributes and levels, and
during interpretation of results. Regarding communication
of patient preference study results to patients, patients
prefer the combination of a lay summary and a detailed
report with visuals. Patients believe the best way to involve
them in the design and conduct of patient preference
studies would be as advisors or collaborators. Open
communication and pre-defined arrangements regarding
expectations, commitment, compensation, and personal
situation are crucial. Considering these requirements in
patient-researcher collaborations during future patient
preference studies could ensure an optimal experience
for patients.
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